IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

1 At present, FDA has approved elranatamab for patients with multiple myeloma who are relapsed/refractory after at least 4 ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...